Want to see SE:BIOG.B full AI Analyst Report?
BioGaia AB (BIOG.B) AI Stock Analysis
BioGaia AB
(Nasdaq OMX AB:BIOG.B)
The score is driven primarily by strong financial quality (high margins, strong ROE, and near-zero leverage), supported by positive technical momentum (price above key moving averages and positive MACD). The main constraint is valuation, with a relatively high P/E and only a modest dividend yield, alongside some recent softening in margins and free cash flow.
BioGaia AB (BIOG.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 12.18B
- Dividend Yield
- 1.36%
- Average Volume (3M)
- 183.44K
- Price to Earnings (P/E)
- 31.1
- Beta (1Y)
- 0.34
- Revenue Growth
- 13.13%
- EPS Growth
- 23.94%
- Country
- Sweden
- Employees
- 251
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
BioGaia AB Business Overview & Revenue Model
Company Description
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The compa...
How the Company Makes Money
BioGaia makes money mainly by commercializing probiotic products and probiotic ingredients built around its Lactobacillus reuteri strains. Its revenue model typically includes: (1) Sales of finished consumer products: BioGaia sells branded probiotic...
BioGaia AB Financial Statement Overview
Summary
High-quality fundamentals: strong profitability with consistently high gross margins and solid EBIT margins, plus an exceptionally conservative balance sheet with effectively zero debt and strong ROE. Offsetting factors are moderating net margins versus 2022–2023 and softer recent free cash flow trends (negative FCF growth in 2024–2025 and further declines in TTM).
Income Statement
86Very PositiveBalance Sheet
94Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.54B | 1.42B | 1.30B | 1.10B | 785.11M |
| Gross Profit | 1.20B | 1.13B | 1.03B | 950.19M | 801.93M | 582.95M |
| EBITDA | 496.12M | 454.33M | 488.29M | 494.92M | 476.89M | 276.86M |
| Net Income | 391.55M | 332.76M | 351.39M | 365.35M | 373.77M | 196.27M |
Balance Sheet | ||||||
| Total Assets | 1.45B | 1.60B | 2.03B | 2.33B | 2.21B | 2.13B |
| Cash, Cash Equivalents and Short-Term Investments | 518.27M | 801.31M | 1.22B | 1.54B | 1.49B | 1.48B |
| Total Debt | 0 | 6.90M | 7.10M | 8.80M | 16.01M | 9.81M |
| Total Liabilities | 229.68M | 283.59M | 310.07M | 305.54M | 241.55M | 250.69M |
| Stockholders Equity | 1.22B | 1.31B | 1.72B | 2.03B | 1.97B | 1.88B |
Cash Flow | ||||||
| Free Cash Flow | 258.38M | 302.97M | 359.06M | 377.25M | 301.03M | 215.50M |
| Operating Cash Flow | 284.45M | 306.57M | 373.22M | 425.96M | 318.94M | 221.88M |
| Investing Cash Flow | -26.21M | -3.34M | -14.07M | -50.94M | -18.14M | -126.97M |
| Financing Cash Flow | -476.20M | -709.87M | -689.72M | -308.42M | -313.59M | -81.85M |
BioGaia AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOG.B, the sentiment is Positive. The current price of 120.40 is below the 20-day moving average (MA) of 121.17, above the 50-day MA of 115.78, and above the 200-day MA of 115.21, indicating a neutral trend. The MACD of 2.11 indicates Positive momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 4.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOG.B.
BioGaia AB Peers Comparison
Overall Rating
- SE:BIOG.B79Outperform
SE:SECARE60.3Neutral
SE:APOTEA58Neutral
SE:ENZY44Neutral
SE:CLBIO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:BIOG.B | 79Outperform | SEK 12.18B | 31.11 | 31.08% | 1.36% | 13.13% | 23.94% |
| SE:SECARE | 60Neutral | SEK 3.04B | 35.19 | 1.24% | 1.47% | 2.73% | 36.67% |
| SE:APOTEA | 58Neutral | SEK 9.59B | 39.05 | ― | 0.65% | 9.35% | -91.93% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| SE:ENZY | 44Neutral | SEK 551.01M | -12.24 | ― | ― | -2.36% | 23.44% |
| SE:CLBIO | 39Underperform | SEK 371.09M | -28.83 | ― | ― | 54.37% | 52.22% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BIOG.B | BioGaia AB Class B | 120.40 | 22.88 | 23.46% | |
| SE:MVIR | Medivir | 1.55 | 1.02 | 191.35% | |
| SE:SECARE | Swedencare AB | 19.00 | -18.06 | -48.73% | |
| SE:APOTEA | Apotea AB | 92.15 | 11.31 | 14.00% | |
| SE:ENZY | Enzymatica AB | 2.27 | 0.32 | 16.41% | |
| SE:CLBIO | Corline Biomedical AB | 14.20 | -5.75 | -28.82% |
BioGaia AB Corporate Events
BioGaia boosts margins and expands probiotic reach in Q3 2026
BioGaia AB reported strong growth for the third quarter of 2026, with net sales rising 23% to SEK 400.4 million and operating profit up 54%, lifting the operating margin to 33%. The Pediatrics and Adult Health segments both delivered double-digit sal...
BioGaia names Nomination Committee for 2027 AGM
BioGaia AB has appointed its Nomination Committee for the 2027 Annual General Meeting, based on the ownership structure as of June 30, 2026 and in line with a previous AGM decision. The committee includes representatives from major shareholders Anato...
BioGaia Sets October 22 Date for Q3 2026 Results and Investor Briefing
BioGaia AB will publish its financial report for the third quarter of 2026 on October 22 at around 8:00 AM CEST, followed by a live audiocast at 9:30 AM CEST where CEO Theresa Agnew and CFO Alexander Kotsinas will present the results and answer quest...
BioGaia to Outline Long-Term Strategy at London Capital Markets Day
BioGaia AB will host a Capital Markets Day in London on December 8, 2026, offering both in-person attendance and a live webcast to reach a broad investor base. The event underscores the company’s intent to deepen engagement with the financial c...
BioGaia launches clinically proven colon health probiotic Colus
BioGaia AB is expanding its adult gut health portfolio with BioGaia Colus, a new probiotic supplement targeting colon health using the proprietary L. reuteri BG-R59 strain and delayed-release vegan capsules designed for delivery to the lower gastroin...
BioGaia Deepens Iberian Partnership With Recordati to Drive Probiotic Growth
BioGaia AB, a Swedish probiotics specialist with a global footprint and a focus on gut, immune and oral health, is deepening its commercial ties in Southern Europe. The company relies on local distribution partners such as Recordati to reach more tha...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026